Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM19 CAR-T Cells in R/R Mantle Cell Lymphoma
NCT05155215Phase 2Unknown
- Sponsor
- Immunochina Pharmaceuticals
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 2, open-label, single-arm trial of IM19 in mantle cell lymphoma (MCL), sponsored by Immunochina Pharmaceuticals. Primary endpoints: Incidence of adverse events (AEs) and abnormal laboratory test results up to 28 days and Objective response rate at 3 months. Status: unknown.
02
Drugs
IM19
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05155215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155215.